Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people using tirzepatide (Mounjaro) in clinical trials lost between 15% and 22% of their body weight over 72 weeks, depending on the dose reached. That is a meaningful range — someone starting at 100 kg might lose 15 kg at one end or over 22 kg at the other. The actual figure for any individual depends on the dose they tolerate, how long they stay on treatment, and the lifestyle changes they make alongside it. Mounjaro is a prescription-only medicine; a clinician reviews every case before treatment begins, and results are never guaranteed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity over 72 weeks. At the highest dose studied (15 mg), participants lost an average of around 20–21% of their body weight. Some analyses put the figure closer to 22.5%. At lower maintenance doses the average falls, which is why the dose your prescriber eventually reaches matters so much to your outcome.
If you want a sense of how much weight you are likely to lose on tirzepatide across different stages of treatment, that is covered in detail separately. If you are starting on the initial dose, our page on how much weight you are likely to lose on 5 mg of Mounjaro is a useful place to get a realistic early benchmark. The broader picture across the full titration schedule is set out on our Mounjaro weight-loss results page.
A few honest caveats: trial participants had structured diet support, regular check-ins and strict adherence monitoring. Real-world results vary. People who stop treatment early, or who are unable to titrate to higher doses because of side effects, typically see smaller losses. The 20%+ figures represent what is achievable under the best conditions, not a floor.
UK private pricing for Mounjaro has shifted since Eli Lilly raised its list price on 1 September 2025. The highest-dose pen's list price moved from around £122 to around £330 for a four-week supply, and typical private market prices since then range roughly £149–£375 per month depending on dose and provider, as widely reported at the time of that change.
Those headline figures often cover only the medicine itself. What they can leave out: the clinical consultation, the prescription fee, delivery, and any ongoing dose-review support or aftercare. Add those separately across a full titration course and the total climbs considerably. If you are trying to plan ahead, our page on how much Mounjaro will cost walks through what to expect at each stage, and current pricing context by dose is covered on the Mounjaro price page.
One practical point: treatment typically starts at 2.5 mg (the dose that lets your system adjust before any therapeutic titration) and monthly costs increase as the dose does. If you are weighing up the full financial commitment before starting, our guide to how much Mounjaro will be gives a clear breakdown to help you plan realistically. Planning for the full course, not just the first pen, gives a more realistic picture of what you are committing to.
Our treatment pricing is shown on the consultation and treatment page. One transparent figure covers the consultation, prescription, medicine, next-working-day DPD delivery and seven-day aftercare. Nothing is billed separately. There is no subscription and no auto-renewal; every repeat order is reviewed by a prescriber before it is processed.
We are not the cheapest option on the market, and that is a deliberate choice. The saving a lower-cost provider offers usually comes from somewhere: thinner clinical oversight, slower turnaround, aftercare you pay extra for, or delivery charges added at checkout. A named prescriber, not software, reads your answers and reviews your consultation the same day it is submitted. Your pen sits in the fridge door (the same fridge it arrived in the next morning) and our clinical team is reachable if anything changes.
Our clinical approach is described in more detail on the about us page, and you can read about our clinical oversight on the clinical team profile.
It is worth being direct about this. Mounjaro is a prescription-only medicine. The MHRA has seized around 20 million doses of illegally traded weight-loss medicines (approximately £45 million street value) and raided the first illicit UK manufacturing site producing counterfeit tirzepatide pens, and the MHRA Yellow Card scheme continues to receive reports of suspect sellers. Fake pens have in some cases contained insulin. The right question is not which provider costs least, but whether the supply chain is legitimate, the clinical oversight is real, and the pharmacy can be verified.
Any regulated UK online pharmacy should be listed on the GPhC pharmacy register. Sellers offering these medicines without a prescription, via social media, or at prices far below the market rate are red flags, not bargains. Report suspect sellers through the Yellow Card scheme.
The tirzepatide treatment landscape (what it is, how it works, and what private access involves) is covered in full on our Mounjaro overview page. If you want to explore treatment options more broadly, the weight-loss treatment overview sets out what is available and how they compare.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.